Aptose Biosciences Inc. logo
Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022
April 25, 2022 07:30 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase...
Aptose Biosciences Inc. logo
Aptose Announces Executive Management Changes
April 07, 2022 07:00 ET | Aptose Biosciences, Inc.
─ Appoints Philippe Ledru as Chief Commercial Officer ─ ─ Announces resignation of CFO/CBO Jotin Marango, MD, PhD ─ SAN DIEGO and TORONTO, April 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences...
Aptose Biosciences Inc. logo
Aptose to Present at Oppenheimer’s 32nd Annual Healthcare Conference
March 01, 2022 07:30 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Inc. logo
Aptose to Participate in Two Biotech Events in January 2022
December 29, 2021 07:30 ET | Aptose Biosciences, Inc.
— H.C. Wainwright BIOCONNECT Virtual Conference — — 11th Annual LifeSci Partners Corporate Access Event — SAN DIEGO and TORONTO, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc....
Aptose Biosciences Inc. logo
Aptose Provides Update on APTO-253 Program
December 20, 2021 07:30 ET | Aptose Biosciences, Inc.
-- Clinical development of the MYC repressor APTO-253 will be discontinued -- -- Company will focus on advancing kinome inhibitor pipeline -- SAN DIEGO and TORONTO, Dec. 20, 2021 (GLOBE NEWSWIRE)...
Aptose Biosciences Inc. logo
HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia
December 13, 2021 16:30 ET | Aptose Biosciences, Inc.
HM43239 Data Featured in Oral Presentation at the American Society of Hematology Annual Meeting Aptose Presents Highlights from Luxeptinib and APTO-253 and Provides Corporate Update SAN DIEGO,...
Aptose Biosciences Inc. logo
Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021
October 26, 2021 07:30 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Inc. logo
Aptose Expands Senior Leadership Team
October 25, 2021 08:00 ET | Aptose Biosciences, Inc.
Janet Clennett, CPA, appointed Vice President, Finance Roger Davies, B.Sc., M. Phil, joins as Vice President, Operations SAN DIEGO and TORONTO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences...
Aptose Biosciences Inc. logo
Aptose to Present at September Investor Conferences
August 30, 2021 07:30 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Inc. logo
Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021
July 20, 2021 16:01 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 20, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...